What is the catalog number for AG490?

The catalog number for AG490 is HY-12000.

What sizes are available for AG490?

AG490 is available in the following size(s): 5 mg, 10 mg, 10 mM - 1 mL, 50 mg, 100 mg, 200 mg.

How many pack sizes does AG490 come in?

AG490 is available in 6 different pack sizes.

AG490 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures AG490?

AG490 is manufactured by QuantiMol.

What is the estimated delivery time for AG490?

Estimated delivery time for AG490 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for AG490?

The safety data sheet for AG490 is available here: http://file.medchemexpress.com/batch_PDF/HY-12000/AG490-SDS-MedChemExpress.pdf.

AG490

AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.

Product Specifications

CAS Number

133550-30-8

Product Name Alternative

Tyrphostin AG490; Tyrphostin B42

UNSPSC

12352005

Hazard Statement

H301, H400

Target

Autophagy; EGFR; JAK; STAT

Type

Reference compound

Related Pathways

Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/AG-490.html

Purity

99.86

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2

Molecular Formula

C17H14N2O3

Molecular Weight

294.30

Precautions

H301, H400

References & Citations

[1]Dowlati A, et al. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther. 2004 Apr;3 (4) :459-63|[2]Wang LH, et al. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation ofIL-2-mediated T cell response. J Immunol. 1999 Apr 1;162 (7) :3897-904.|[3]Davoodi-Semiromi A, et al. The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice. PLoS One. 2012;7 (5) :e36079.|[4]Cheppudira BP, et al. Anti-hyperalgesic effects of AG490, a Janus kinase inhibitor, in a rat model of inflammatory pain. Biomed Rep. 2015 Sep;3 (5) :703-706.